Synlogic (NASDAQ:SYBX) Stock Price Crosses Below 50-Day Moving Average of $2.20

Synlogic, Inc. (NASDAQ:SYBXGet Free Report)’s stock price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $2.20 and traded as low as $1.73. Synlogic shares last traded at $1.79, with a volume of 71,781 shares changing hands.

Analysts Set New Price Targets

SYBX has been the topic of several analyst reports. Alliance Global Partners initiated coverage on Synlogic in a research note on Monday, December 11th. They issued a “buy” rating and a $30.00 target price on the stock. SVB Leerink restated a “market perform” rating on shares of Synlogic in a report on Friday, February 9th. Leerink Partnrs downgraded Synlogic from an “outperform” rating to a “market perform” rating in a report on Friday, February 9th. Chardan Capital downgraded Synlogic from a “buy” rating to a “neutral” rating in a report on Friday, February 9th. Finally, HC Wainwright upgraded Synlogic from a “sell” rating to a “neutral” rating in a report on Wednesday, March 20th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $65.00.

View Our Latest Analysis on SYBX

Synlogic Stock Up 1.7 %

The firm has a fifty day simple moving average of $2.20 and a 200-day simple moving average of $2.73. The company has a market capitalization of $20.85 million, a P/E ratio of -0.16 and a beta of 1.09.

Synlogic (NASDAQ:SYBXGet Free Report) last posted its quarterly earnings data on Tuesday, March 19th. The biotechnology company reported ($1.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.60). The firm had revenue of $2.77 million for the quarter, compared to the consensus estimate of $2.71 million. Synlogic had a negative return on equity of 109.34% and a negative net margin of 1,699.23%. On average, sell-side analysts predict that Synlogic, Inc. will post -2.09 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Synlogic by 26.0% during the fourth quarter. Vanguard Group Inc. now owns 188,433 shares of the biotechnology company’s stock worth $725,000 after buying an additional 38,862 shares in the last quarter. Citadel Advisors LLC bought a new position in shares of Synlogic during the fourth quarter worth about $42,000. Armistice Capital LLC grew its holdings in shares of Synlogic by 75.9% during the fourth quarter. Armistice Capital LLC now owns 1,055,000 shares of the biotechnology company’s stock worth $4,062,000 after buying an additional 455,126 shares in the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Synlogic by 43.4% during the fourth quarter. Harbor Capital Advisors Inc. now owns 30,685 shares of the biotechnology company’s stock worth $118,000 after buying an additional 9,282 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new position in shares of Synlogic during the third quarter worth about $35,000. 63.40% of the stock is currently owned by institutional investors.

Synlogic Company Profile

(Get Free Report)

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

Featured Articles

Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.